Literature DB >> 16082709

Failure to confirm association between RGS4 haplotypes and schizophrenia in Caucasians.

Janet L Sobell1, Christian Richard, Donna A Wirshing, Leonard L Heston.   

Abstract

The regulator of G-protein signaling (RGS) and RGS-like proteins are a diverse family of over 30 molecules that function as GTPase activating proteins for Galpha subunits of the Gq and Gi families of heterotrimeric guanine nucleotide-binding proteins (G proteins). By accelerating GTPase activity, RGS proteins drive G proteins into their inactive GDP-bound forms. G-protein coupled dopamine, metabotropic glutamate, and other neurotransmitter receptors can be modulated by RGS4, the predominant form in brain. The recent finding of decreased RGS4 mRNA expression in post-mortem brains from schizophrenic patients, coupled with the map position of RGS4 to a region previously linked to schizophrenia, as well as other biological data, prompted the investigation of the gene as a disease candidate. Multiple family-based and case-control association studies have been conducted, with modest and conflicting support for particular single nucleotide polymorphism (SNP) markers and SNP marker haplotypes. The present case-control analysis of 568 patients and 689 controls, one of the largest single studies to date, failed to confirm support for association of particular RGS4 SNP alleles, or for association of any particular four, three, or two SNP haplotype. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082709     DOI: 10.1002/ajmg.b.30221

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  12 in total

Review 1.  Genomic structural variation and schizophrenia.

Authors:  Jennifer Gladys Mulle
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

2.  RGS4 genotype is not associated with antipsychotic medication response in schizophrenia.

Authors:  O Kampman; A Illi; K Hänninen; H Katila; S Anttila; R Rontu; K M Mattila; E Leinonen; T Lehtimäki
Journal:  J Neural Transm (Vienna)       Date:  2006-04-11       Impact factor: 3.575

3.  Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia.

Authors:  Kristin K Nicodemus; Bhaskar S Kolachana; Radhakrishna Vakkalanka; Richard E Straub; Ina Giegling; Michael F Egan; Dan Rujescu; Daniel R Weinberger
Journal:  Hum Genet       Date:  2006-09-28       Impact factor: 4.132

4.  Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment.

Authors:  G Rivero; A M Gabilondo; J A García-Sevilla; L F Callado; R La Harpe; B Morentin; J J Meana
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

5.  RGS4 polymorphisms associated with variability of cognitive performance in a family-based schizophrenia sample.

Authors:  Konasale M Prasad; Laura Almasy; Ruben C Gur; Raquel E Gur; Michael Pogue-Geile; Kodavali V Chowdari; Michael E Talkowski; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2009-03-12       Impact factor: 9.306

6.  Linkage disequilibrium patterns and functional analysis of RGS4 polymorphisms in relation to schizophrenia.

Authors:  Kodavali V Chowdari; Mikhil Bamne; Joel Wood; Michael E Talkowski; Karoly Mirnics; Pat Levitt; David A Lewis; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2007-05-21       Impact factor: 9.306

Review 7.  Can RGS4 polymorphisms be viewed as credible risk factors for schizophrenia? A critical review of the evidence.

Authors:  Michael E Talkowski; Kv Chowdari; David A Lewis; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2006-02-09       Impact factor: 9.306

8.  Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

Authors:  Daniel B Campbell; Philip J Ebert; Tara Skelly; T Scott Stroup; Jeffrey Lieberman; Pat Levitt; Patrick F Sullivan
Journal:  Biol Psychiatry       Date:  2007-06-22       Impact factor: 13.382

9.  Association of RGS2 and RGS5 variants with schizophrenia symptom severity.

Authors:  Daniel B Campbell; Leslie A Lange; Tara Skelly; Jeffrey Lieberman; Pat Levitt; Patrick F Sullivan
Journal:  Schizophr Res       Date:  2008-02-11       Impact factor: 4.939

Review 10.  Dopaminergic intracellular signal integrating proteins: relevance to schizophrenia.

Authors:  Bruno R Souza; Renan P Souza; Daniela V F Rosa; Melissa M Guimarães; Humberto Correa; Marco A Romano-Silva
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.